Category: Diabetes

Introduction and Objective: T1D Exchange Quality Improvement Collaborative (T1DX-QI) administered a survey to evaluate characteristics of patient and clinic workforce and QI initiatives underway to support people with type 1 and type 2 diabetes (PwT1D and PwT2D).Methods: The T1DX-QI survey was administered August-October 2025 to collect 2024 data. Descriptive analyses summarized racial/ethnic diversity of clinical […]

Introduction and Objective: Fatty liver index (FLI) is a diagnostic tool in metabolic dysfunction-associated steatotic liver disease, an end-organ complication in overweight/obesity. This post hoc analysis assessed the impact of injectable semaglutide (sema) 2.4 mg versus placebo on FLI scores in STEP 1.Methods: People with information needed to calculate FLI scores (BMI, waist circumference, triglycerides […]

Introduction and Objective: Diabetic peripheral neuropathy remains a major therapeutic challenge, with over 50% of patients responding inadequately to existing non-opioid therapies (gabapentinoids, SNRIs, TCAs). Dorsal root ganglion (DRG) neurons serve as the primary sites for injury-induced plasticity underlying painful peripheral pathophysiologies. Voltage-gated sodium channels (VGSC), specifically Nav1.8, are highly expressed in DRGs and are […]

Introduction and Objective: In the SURPASS-4 clinical trial in patients with type 2 diabetes (T2D) at high cardiovascular risk, once-weekly treatment with the dual GLP-1/GIP receptor agonist, tirzepatide (TZP) resulted in substantial weight reduction, slower kidney function decline, and reduced albuminuria compared to insulin glargine. This post-hoc analysis evaluated the effect of TZP on 52-week […]

Introduction and Objective: Body mass index (BMI) alone may miss obesity risk; ICMR-INDIAB study supports metabolic phenotyping into four groups based on their metabolic and BMI status: metabolically healthy non-obese (MHNO), metabolically obese non-obese (MONO), metabolically obese obese (MOO), and metabolically healthy obese (MHO). We assessed phenotype distribution and association with liver fibrosis stage using […]

Introduction and Objective: The rates of screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis-4 (FIB-4) index is slowly increasing in the primary care setting. Access to Vibration-Controlled Transient Elastography (FibroScan) remains a barrier in identifying high-risk MASLD and is currently underutilized. We evaluate an approach to implementation of […]

Introduction and Objective: People with diabetes (PWD) who are beneficiaries of Medicaid have worse glycemic outcomes than those with private insurance and are at increased risk for poor clinical outcomes. Barriers to accessing automated insulin delivery (AID) systems include age, complex/extensive prior authorization policies, unclear documentation requirements, and healthcare provider implicit bias about who is […]

Introduction and Objective: Mobile app-based weight management programmes using artificial intelligence (AI) coaching are increasingly used to support lifestyle change in people with type 2 diabetes (T2D), but real-world outcomes remain limited. The aim of this study was to evaluate weight loss among adults with T2D using an AI-enabled weight management app, and to examine […]

Introduction and Objective: Insulin is secreted into the portal vein in response to nutrient ingestion. However, a significant proportion is extracted as it traverses the liver prior to reaching the systemic circulation. The effect of glucagon on hepatic extraction is uncertain. This is particularly germane to situations where postprandial suppression of glucagon is impaired, theoretically […]

Introduction and Objective: Gestational diabetes (GDM) and hypertensive disorders of pregnancy often co-occur and are the leading causes of maternal morbidity. We aimed to examine whether the risks of GDM and new-onset postpartum diabetes (PPDM) increase across gestational blood pressure (BP) categories following the current guidelines with lower thresholds for hypertension (systolic/diastolic BP ≥130/80 mmHg) […]